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Introduction
Hypercholesterolemia is one of the major risk factors
for cardiovascular disease.1,2 Recent clinical outcome
studies with statins demonstrated significant reductions
in mortality and cardiovascular-related events for a
mean 25–35% reduction in low-density lipoprotein
(LDL) cholesterol.3,4 Accordingly, there is a trend
towards setting the therapeutic goal of LDL cholesterol
reduction to at least this magnitude in most patients.
However, in a recent survey (Lipid Treatment
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Assessment Project, L-TAP),5 only 32–46% of patients
reached the target LDL cholesterol levels determined
by the US National Cholesterol Education Program
(NCEP) Adult Treatment Panel (ATP) II.6 Further,
although most patients in the Scandinavian Simvastatin
Survival Study (4S) reached the study goal of total
cholesterol less than 200 mg/dL, some patients might
have benefited from additional cholesterol-lowering.3
Fluvastatin is a wholly synthetic 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitor that has been shown to reduce LDL
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cholesterol levels by 20–26% at a dosage of 20–40
mg/day in clinical studies completed in more than
2,500 patients with hypercholesterolemia in Europe
and North America.7,8 The dose-response curves for
LDL cholesterol reduction with most HMG-CoA
reductase inhibitors are log-linear and, with dosage
doubling, an additional reduction in LDL cholesterol
level of approximately 6% is observed.9–11 A slow-release
formulation of fluvastatin 80 mg was introduced
worldwide as a new once-a-day dose offering enhanced
LDL cholesterol lowering while retaining an excellent
safety profile.4 The current study was designed to
compare the efficacy and safety of slow-release fluvastatin
80 mg/day with immediate-release fluvastatin 40 mg/
day regarding LDL cholesterol reduction when both
regimens were administrated at bedtime in Chinese
patients with primary hypercholesterolemia.
Methods
Study population
Men and women (who were not pregnant or lactating)
who were aged * 18 years with primary hyper-
cholesterolemia (LDL cholesterol * 160 mg/dL,
triglycerides ) 400 mg/dL) were eligible for inclusion
in this study. Patients were excluded if they had severe
uncontrolled hypertension, congestive heart failure,
severe or unstable angina pectoris, diabetes mellitus,
uncontrolled hypothyroidism, renal impairment (serum
creatinine > 1.5 times the upper limit of normal
[ULN]), chronic liver disease, or elevated serum
transaminase levels (alanine transaminase [ALT] or
aspartate transaminase [AST] > 1.5 times the ULN),
muscle disease of any type, or elevated serum creatine
kinase level (creatine kinase > twice the ULN). Other
exclusion criteria included any acute illness or severe
trauma within the 3 months before study, and
myocardial infarction, major surgery, or percutaneous
transluminal coronary angioplasty within the 6 months
before study. Concomitant treatment with oral
contraceptives, any systemic steroid hormones, oral
anticoagulants, or other lipid-lowering agents, was
not permitted during the study.
Study design
This was an open-label, active-controlled randomized
study involving 2 parallel groups. Patients were screened
for eligibility 4 weeks before study entry (week –4) and
at baseline (week 0). During this 4-week placebo/
dietary run-in period, 1 placebo capsule was
administered daily at bedtime. Patients were instructed
about, and encouraged to maintain, an NCEP step I or
II diet throughout the study. At the first screening
visit, written informed consent approved by our
institutional review board was obtained from each
patient and medical histories were reviewed. Eligible
patients who completed the run-in period entered a
12-week treatment phase with either a slow-release
fluvastatin 80-mg tablet, or an immediate-release
fluvastatin 40-mg capsule, each administered once
daily at bedtime. Patients were asked to attend the
center on 7 occasions during the trial (screening, week
–2, baseline, and weeks 2, 4, 8 and 12). At each of
these visits, adverse events, concomitant medication
usage, and treatment compliance, were recorded. The
total study duration for each patient, including the
placebo/dietary run-in period, was 16 weeks.
Efficacy criteria
The primary efficacy endpoint was the mean percent
change in LDL cholesterol level from baseline to study
end. Secondary efficacy variables were percent changes
from baseline to study end in total cholesterol, high-
density lipoprotein (HDL) cholesterol, triglyceride,
apolipoprotein A1 and apolipoprotein B levels, and
the percent of patients attaining NCEP ATP II target
LDL cholesterol levels: for patients with coronary
heart disease (CHD), < 100 mg/dL; for patients
without CHD but with * 2 risk factors for CHD, < 130
mg/dL; and for patients without CHD and < 2 risk
factors for CHD, < 160 mg/dL.
Safety criteria
Safety and tolerability were evaluated by adverse event
reporting, laboratory studies and recording of vital
signs. Patients were questioned at every visit about
the occurrence of adverse events using non-leading
questions. A physical examination and electrocar-
diogram were performed on day 1 and at study end.
Fasting blood chemistry, complete blood count,
urinalysis parameters, and thyroid stimulating hormone
levels were measured during the study. Patients with
elevated ALT or AST levels to * 3 times the ULN were
retested within 1 week; persistence of such elevation
led to patient discontinuation. Patients with
unexplained elevation of creatine kinase to * 10 times
the ULN were also discontinued from the study.
Statistical analysis
The primary efficacy endpoint, the percent decrease
from baseline in LDL cholesterol, was calculated from
the mean of the final 3 measurements in the run-in
phase and the measurement after 12 weeks of treatment.
The results were analyzed on an intention-to-treat
basis. A series of secondary endpoints were also
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evaluated, including percent and mean absolute changes
in total cholesterol, HDL cholesterol, and triglyceride
levels, and the percent of patients attaining NCEP
ATP II target levels for LDL cholesterol. Continuous
variables were expressed as mean ± standard deviation
(SD). To assess the efficacy of treatment, paired com-
parisons before and after treatment were performed
using the paired t test. Comparisons between the 80
mg/day and 40 mg/day groups were performed using
the 2-sample t test. Categoric variables were analyzed
using the Chi-squared test. Statistical significance was
set at p < 0.05. Safety results were reported for all
randomized patients who had received at least 1 dose
of active medication.
Results
Demographic and clinical characteristics
Of the 109 patients screened, 61 met entry criteria and
were randomized to treatment with slow-release
fluvastatin 80 mg/day (n = 31) or immediate-release
fluvastatin 40 mg/day (n = 30). Six patients in the 80
mg group and 10 in the 40 mg group had a history of
CHD. One patient in the 80 mg group and 3 in the 40
mg group had a history of other atherosclerotic diseases;
all of these patients also had CHD. Otherwise, there
were no significant differences between treatment
groups regarding baseline demographic characteristics.
Of the 61 patients randomized, 52 completed the
study. In the 80 mg group, 3 patients discontinued the
study because of adverse events (back pain, abdominal
pain) or laboratory abnormalities. In the 40 mg group,
6 patients discontinued the study because of adverse
events (impaired urination, abnormal liver function
tests), prohibited medication used, concomitant illness,
loss to follow-up, or withdrawal of consent (Table 1).
Effects on lipids and lipoproteins
Lipid and lipoprotein levels were compatible between
the 2 treatment groups at baseline. Figure 1 and Table
2 summarize the effects of treatment on lipid and
lipoprotein levels at baseline and after treatment.
After 12 weeks of fluvastatin therapy plus an NCEP
step I or II diet, the mean percent decrease from
baseline in LDL cholesterol level was 29.9% for the 80
mg/day group (from 186 ± 33 to 130 ± 41 mg/dL,
p < 0.0001) and 22.5% for the 40 mg/day group
(from 191 ± 33 to 148 ± 42 mg/dL, p < 0.0001).
Table 1. Demographic data of study patients
Fluvastatin
p
80 mg/day (n = 31) 40 mg/day (n = 30)
Age (yr) 64 ± 12 64 ± 12 0.968
Gender (M/F) 16/15 13/17 0.528
Weight (kg) 64 ± 10 61 ± 10 0.139
Height (cm) 159 ± 7 158 ± 9 0.671
Body mass index (kg/m2) 25.3 ± 3.0 24.1 ± 2.9 0.112
Systolic blood pressure (mmHg) 125 ± 16 125 ± 16 0.828
Diastolic blood pressure (mmHg) 77 ± 9 76 ± 9 0.943
Heart rate (beats/min) 68 ± 8 70 ± 8 0.297
Previous statin therapy, n (%) 13 (41.9) 15 (50.0) 0.483
Values shown are mean ± standard deviation unless indicated otherwise.
Figure 1. Effects of 12 weeks of treatment with fluvastatin 40
mg/day versus 80 mg/day on plasma lipid and lipoprotein pro-
files in 61 Chinese patients with primary hypercholesterolemia.
There were no significant differences between the 2 groups
regarding changes in levels of low-density lipoprotein (LDL)
cholesterol, total cholesterol (TC), high-density lipoprotein (HDL)
cholesterol, triglycerides (TG), apolipoprotein A1 (ApoA1) and
apolipoprotein B (ApoB).
LDL TC HDL TG ApoA1 ApoB
5
0
–5
–10
–15
–20
–25
–30
C
ha
ng
e 
fr
om
 b
as
el
in
e 
(%
)
40 mg/day
80 mg/day
C.C. Wu, et al
J Chin Med Assoc • August 2005 • Vol 68 • No 8356
The percent changes in LDL cholesterol were not
significantly different between the 2 groups (p =
0.087). The proportion of patients with a more than
15% reduction from baseline in LDL cholesterol level
was 77% in the 80 mg/day group and 70% in the 40
mg/day group. Overall, more patients in the 80 versus
40 mg/day group reached LDL cholesterol goals of
the NCEP ATP II (65% vs 37% of patients, p < 0.05;
Table 3).
The reductions in total cholesterol levels were
22.5% (from 266 ± 37 to 204 ± 45 mg/dL) in the
fluvastatin 80 mg/day group and 17.3% (from 269 ±
40 to 222 ± 45 mg/dL) in the 40 mg/day group.
HDL cholesterol levels increased slightly by 5.6% in
the 80 mg/day group (47 ± 11 to 50 ± 13 mg/dL),
and by 5.2% in the 40 mg/day group (from 48 ± 12 to
50 ± 13 mg/dL). The reduction in triglyceride levels
was 14% (from 151 ± 68 to 123 ± 50 mg/dL) in the
40 mg/day group and 12.3% (from 158 ± 66 to 124 ±
49 mg/dL) in the 80 mg/day group. Apolipoprotein
A1 levels increased by 8.7% in the 80 mg/day group
(from 131 ± 27 to 143 ± 26 mg/dL), and by 7.8%
(from 135 ± 22 to 143 ± 29 mg/dL) in the 40 mg/
day group. Apolipoprotein B levels decreased by
25.4% (from 150 ± 29 to 113 ± 28 mg/dL) in the 80
mg/day group, and by 19.5% (from 155 ± 30 to 121 ±
30 mg/dL) in the 40 mg/day group. Percent changes
in total cholesterol, triglyceride, HDL cholesterol,
Table 2. Effects of fluvastatin 40 mg/day and 80 mg/day on fasting lipid and lipoprotein profiles
Baseline (mg/dL) Week 12 (mg/dL) % change 95% confidence interval p*
Total cholesterol
40 mg/day 269 ± 40 222 ± 45 –17.3 –17.5, –27.5 0.140
80 mg/day 266 ± 37 204 ± 45 –22.5 –12.1, –22.5
LDL cholesterol
40 mg/day 191 ± 33 148 ± 42 –22.5 –16.1, –28.8 0.087
80 mg/day 186 ± 33 130 ± 41 –29.9 –23.7, –36.0
HDL cholesterol
40 mg/day 48 ±  12 50 ±  13 5.2 –1.3, 11.6 0.917
80 mg/day 47 ±  11 50 ±  13 5.6 –0.6, 11.9
Triglycerides
40 mg/day 151 ± 68 123 ± 50 –14.0 –3.7, –24.3 0.813
80 mg/day 158 ± 66 124 ± 49 –12.3 –2.4, –22.3
Apolipoprotein A1
40 mg/day 135 ± 22 143 ± 29 7.8 –0.3, 15.9 0.855
80 mg/day 131 ± 27 143 ± 26 8.7 –1.4, 16.0
Apolipoprotein B
40 mg/day 155 ± 30 121 ± 30 –19.5 –15.8, –27.1 0.079
80 mg/day 150 ± 29 113 ± 28 –25.4 –22.7, –33.2
*p values between groups. Values for all parameters are mean ± standard deviation.
Table 3. Patients reaching low-density lipoprotein cholesterol (LDL-C) goals (responders) of the US National Cholesterol
Education Program at study end
Risk category LDL-C goal
Fluvastatin 80 mg/day Fluvastatin 40 mg/day
Patients, n Responders, n (%) Patients, n Responders, n (%)
CHD < 100 mg/dL 6 1 (17) 10 0 (0)
* 2 risk factors < 130 mg/dL 20 16 (80) 18 9 (50)
< 2 risk factors < 160 mg/dL 5 3 (60) 2 2 (100)
All categories – 31 20 (65) 30 11 (37)
CHD = coronary heart disease.
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apolipoprotein A1, and apolipoprotein B levels were
not statistically significantly different between the 2
treatment groups.
Safety
No statistically significant differences were found in
the incidence of adverse events between the 2
treatment groups. Overall, 9 patients (29%) in the
fluvastatin 80 mg/day group and 3 (10%) in the 40
mg/day group reported adverse events during
treatment, but the difference was not significant (p =
0.105). Drug-related myalgia occurred in 4 patients
(12.9%) in the 80 mg/day group, but in none in the
40 mg/day group. No cases of myalgia were critical
or notable as defined by the study protocol (i.e.
accompanied by elevations of creatine kinase to * 5
times the ULN).
The incidence of serum transaminase elevations to
more than 3 times the ULN on non-consecutive (not
notable) or 2 consecutive (notable) occasions was
similar between the 2 treatment groups (3.2% in the
80 mg/day group, and 3.5% in the 40 mg/day group).
No critical (* 5 times the ULN) or notable (* 10 times
the ULN) creatine kinase elevations were observed in
either treatment group.
Two patients in the fluvastatin 80 mg/day group
had non-fatal, serious adverse events during treatment
(abdominal pain and coronary artery disorder), yet
neither of these events was considered by the
investigators to be related to the study medication. No
clinically significant differences in vital signs, body
weight, or abnormalities on physical examination,
were noted between the 2 treatment groups.
Discussion
This study showed that, in Chinese patients with
primary hypercholesterolemia, doubling the dosage of
fluvastatin from 40 to 80 mg once daily at bedtime
resulted in an additional 7.5% decrease in LDL
cholesterol level. Further, the 80 mg/day schedule
was well tolerated, with an adverse effect profile similar
to that of the 40 mg/day regimen.
Trends exist towards greater LDL cholesterol
reductions in some patients during treatment with
higher rather than lower dosages of statins, even
though dose-response curves for statins are curvilinear
and not proportional. In general, doubling statin
dosages above minimal effective levels will decrease
LDL cholesterol by an additional 6%.9,10 However,
ethnic differences exist in dose-response relationships
for statins, as demonstrated in the Expanded Clinical
Evaluation of Lovastatin (EXCEL) study.12 Thus, it
was necessary to determine the efficacy and safety of
doubling the dosage of fluvastatin from 40 to 80 mg/
day in the Chinese population.
In the present study, such doubling of the fluvastatin
dosage caused an additional 7.5% decrease in LDL
cholesterol from baseline, which is greater than the 6%
decrease reported in earlier studies.9,10 The mean LDL
cholesterol decrease in the current study was 22.5% in
the fluvastatin 40 mg/day group; this is consistent
with previous studies in Europe and North America
that demonstrated a 24% decrease in LDL cholesterol
with this dosage.7 Although the additional LDL
cholesterol reduction with the fluvastatin 80 mg/day
versus 40 mg/day schedule in the current study was
not statistically significant, it still allowed almost twice
as many patients to attain goals for LDL cholesterol
suggested by NCEP ATP II, which emphasize more
intensive LDL cholesterol lowering in patients with
established CHD. Soon after the completion of our
study, updated NCEP ATP III guidelines were released,
and the importance of intensive LDL cholesterol
lowering was extended to certain patients with high
CHD risk, even in cases of primary prevention.13
Fluvastatin increased HDL cholesterol by 5.2% in
the 40 mg/day group, and by 5.6% in the 80 mg/day
group. These elevations in HDL cholesterol were
smaller than in a previous study in Europe and North
America, which demonstrated a mean increase of
7.8%.7 The determinants of HDL cholesterol response
to statins are not well defined. In a study in Israel of
fluvastatin 40 mg/day in patients with heterozygous
familial hypercholesterolemia, changes in HDL
cholesterol were related to a specific LDL-receptor
mutation, to several constitutional factors, and to
baseline lipid profiles.14 Whether differences exist
between Chinese and Caucasian populations
regarding HDL cholesterol responses to statins
requires further investigation in larger numbers of
patients.15
In the present study, triglyceride levels were
reduced by 12.3% in the fluvastatin 80 mg/day
group, and by 14% in the 40 mg/day group. This was
similar to results from another study in Chinese
patients in Hong Kong, which showed that fluvastatin
20–40 mg/day reduced serum triglyceride levels by
12%.16 Data from previous studies in Europe and
North America showed that fluvastatin 40 mg/day
reduced triglyceride levels by 10.6%.7 Although the
triglyceride-lowering effects of statins are usually
dose-dependent,12 in our study, the 80 mg/day
group did not have a markedly greater reduction in
triglycerides than the 40 mg/day group, despite
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similar baseline triglyceride and HDL cholesterol
levels. The effects of statins on HDL cholesterol and
triglyceride levels depend not only on dosage, but
also on baseline lipid levels, i.e. the higher the baseline
triglyceride level, the greater the subsequent change.17
It remains to be determined whether the lack of
difference in triglyceride-lowering is related to the
ceiling effect or the small sample size.
No significant difference in the incidence of adverse
events was noted between the 2 fluvastatin groups in
our study. The most important adverse events
associated with statins are myopathy and asymptomatic
increases in serum transaminase levels.18 However,
no patients developed myopathy (muscle pain
accompanied by an increase in creatine kinase to * 10
times the ULN); further, none of the 4 patients in the
80 mg/day group who developed myalgia had critical
or notable creatine kinase elevations as defined by the
study protocol. Although dose-dependent increases
in transaminase levels have been observed during
statin therapy,5 there were no such increases in, and
no differences between, the 2 fluvastatin groups in
our study. These results indicate that fluvastatin 80
mg/day is equally as safe and well tolerated as a 40
mg/day regimen in Chinese patients.
Although the sample size in the present study was
relatively small, the lipid-lowering effects of fluvastatin
were consistent with published data.7,8 Nevertheless,
we acknowledge that, because of our small sample
size, there may have been insufficient statistical power
to demonstrate a difference between the 2 fluvastatin
schedules.
In conclusion, in Chinese patients with primary
hypercholesterolemia, doubling the dosage of
fluvastatin from 40 mg to 80 mg once daily is effective
and safe in terms of reducing LDL cholesterol; such
dosage doubling might also permit more treated
patients to achieve NCEP ATP II goals for LDL
cholesterol.
Acknowledgments
This study was supported by Novartis (Taiwan) Co
Ltd. We are indebted to Drs. Ming-Shium Tu, Chi-
Jen Tseng, Chih-Cheng Leu, Chia-Ting Chao and
Cheng-Ju Wu for their assistance in enrolling patients.
References
1. Stamler J, Wentworth D, Neaton JD. Is relationship between
serum cholesterol and risk of premature death from coronary
heart disease continuous and graded? Findings in 356,222
primary screenees of the Multiple Risk Factor Intervention
Trial (MRFIT). JAMA 1986;256:2823–8.
2. Sytkowski PA, Kannel WB, D’Agostino RB. Changes in risk
factors and the decline in mortality from cardiovascular
disease. The Framingham Heart Study. N Engl J Med 1990;
22:1635–41.
3. Randomised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Survival
Study (4S). Lancet 1994;344:1383–9.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR,
MacFarlane PW, Packard CJ, et al. Prevention of coronary
heart disease with pravastatin in men with hypercholesterolemia.
West of Scotland Coronary Prevention Study Group. N Engl J
Med 1995;333:1301–7.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment
assessment project (L-TAP): a multicenter survey to evaluate
the percentages of dyslipidemic patients receiving lipid-lowering
therapy and achieving low-density lipoprotein cholesterol goals.
Arch Intern Med 2000;160:459–67.
6. Summary of the second report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel II). JAMA 1993;269:3015–23.
7. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug
treatment of dyslipoproteinemia, with a focus on the new
HMG-CoA reductase inhibitor fluvastatin. Circulation 1993;
87:45–53.
8. Peters TK, Mehra M, Muratti EN. Efficacy and safety of
fluvastatin in hypertensive patients: an analysis of a clinical trial
database. Am J Hypertens 1993;6:340–5.
9. Davidson MH, Stein EA, Dujovne CA, Hunninghake DB,
Weiss SR, Knopp RH, Illingworth DR, et al. The efficacy and
six-week tolerability of simvastatin 80 and 160 mg/day. Am J
Cardiol 1997;79:38–42.
10. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton
M, Franklin FA, Hurley DP, et al. Expanded Clinical Evaluation
of Lovastatin (EXCEL) study results: I. Efficacy in modifying
plasma lipoproteins and adverse event profile in 8245 patients
with moderate hypercholesterolemia. Arch Intern Med 1991;
151:43–9.
11. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz
SL, Lupien PJ, Black DM, et al. Reduction of LDL cholesterol
by 25% to 60% in patients with primary hypercholesterolemia
by atorvastatin, a new HMG-CoA reductase inhibitor.
Arterioscler Thromb Vasc Biol 1995;15:678–82.
12. Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH,
Chremos AN, Langendorfer A, et al. Expanded Clinical
Evaluation of Lovastatin (EXCEL) study results: effect of
patient characteristics on lovastatin-induced changes in plasma
concentrations of lipids and lipoproteins. Circulation 1992;
85:1293–303.
13. Executive summary of the third report of the National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III). JAMA
2001;285:2486–97.
14. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N,
Dann EJ, Wurm M, et al. Genetic determinants of responsiveness
to the HMG-CoA reductase inhibitor fluvastatin in patients
with molecularly defined heterozygous familial hyper-
cholesterolemia. Circulation 1993;87:35–44.
15. Yu WC, Chen CH, Tsao HM, Ding YA. A randomized,
double-blind comparison of cerivastatin and lovastatin for
treatment of primary hypercholesterolemia. J Chin Med Assoc
2002;65:260–7.
16. Tomlinson B, Mak TW, Tsui JY, Woo J, Shek CC, Critchley
Slow-release fluvastatin in hypercholesterolemia
J Chin Med Assoc • August 2005 • Vol 68 • No 8 359
JA, Masarei JR, et al. Effects of fluvastatin on lipid profile and
apolipoproteins in Chinese patients with hypercholesterolemia.
Am J Cardiol 1995;76:136–9.
17. Ballantyne CM, Pazzucconi F, Pinto X, Reckless JP, Stein E,
McKenney J, Bortolini M, et al. Efficacy and tolerability of
fluvastatin extended-release delivery system: a pooled analysis.
Clin Ther 2001;23:177–92.
18. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA
reductase inhibitors in the prevention of coronary heart disease:
a reappraisal. Drug Saf 1996;14:11–24.
